(Q38266290)

1 September 2017

1 reference

title

A review of gliptins for 2014. (English)

1 reference

1 September 2017

André J Scheen

1

1 reference

1 September 2017

language of work or name

English

0 references

publication date

10 November 2014

1 reference

Expert Opinion on Pharmacotherapy

1 September 2017

published in

1 reference

1 September 2017

volume

16

1 reference

1 September 2017

issue

1

1 reference

1 September 2017

page(s)

43-62

1 reference

A review of gliptins in 2011.

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Sitagliptin: a review of its use in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Saxagliptin overview: special focus on safety and adverse effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Gemigliptin, a novel dipeptidyl peptidase 4 inhibitor: first new anti-diabetic drug in the history of Korean pharmaceutical industry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacokinetics of dipeptidylpeptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidylpeptidase-4 inhibitors (gliptins): focus on drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacokinetics in patients with chronic liver disease and hepatic safety of incretin-based therapies for the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Comparative effectiveness of dipeptidylpeptidase-4 inhibitors in type 2 diabetes: a systematic review and mixed treatment comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor gemigliptin compared with sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Comparison of vildagliptin twice daily vs. sitagliptin once daily using continuous glucose monitoring (CGM): crossover pilot study (J-VICTORIA study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A novel model-based meta-analysis to indirectly estimate the comparative efficacy of two medications: an example using DPP-4 inhibitors, sitagliptin and linagliptin, in treatment of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of sitagliptin and metformin treatment on incretin hormone and insulin secretory responses to oral and "isoglycemic" intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of sitagliptin on glycemia, incretin hormones, and antropyloroduodenal motility in response to intraduodenal glucose infusion in healthy lean and obese humans and patients with type 2 diabetes treated with or without metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacology, physiology, and mechanisms of incretin hormone action

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of dipeptidyl peptidase-4 inhibitors in type 2 diabetes: meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Head-to-head comparison of dipeptidyl peptidase-IV inhibitors and sulfonylureas - a meta-analysis from randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of initial combination therapy with alogliptin plus metformin versus either as monotherapy in drug-naïve patients with type 2 diabetes: a randomized, double-blind, 6-month study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Metformin + saxagliptin for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Linagliptin plus metformin: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of Jentadueto® (linagliptin plus metformin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of adding pioglitazone or sitagliptin to patients with type 2 diabetes insufficiently controlled with metformin and a sulfonylurea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Combination therapy with DPP-4 inhibitors and insulin in patients with type 2 diabetes mellitus: what is the evidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Comparison between sitagliptin as add-on therapy to insulin and insulin dose-increase therapy in uncontrolled Korean type 2 diabetes: CSI study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of add-on treatment with sitagliptin on narrowing the range of glucose fluctuations in Japanese type 2 diabetes patients receiving insulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Improved glycaemic control with vildagliptin added to insulin, with or without metformin, in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Clinical evidence and mechanistic basis for vildagliptin's effect in combination with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of adding linagliptin to basal insulin regimen for inadequately controlled type 2 diabetes: a ≥52-week randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Insulin plus incretin: A glucose-lowering strategy for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The DPP-IV inhibitor linagliptin and GLP-1 induce synergistic effects on body weight loss and appetite suppression in the diet-induced obese rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effect of linagliptin, alone and in combination with voglibose or exendin-4, on glucose control in male ZDF rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A randomized non-inferiority study comparing the addition of exenatide twice daily to sitagliptin or switching from sitagliptin to exenatide twice daily in patients with type 2 diabetes experiencing inadequate glycaemic control on metformin and sita

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label tr

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Addition of incretin therapy to metformin in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

GLP-1 receptor agonists or DPP-4 inhibitors: how to guide the clinician?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Predicting efficacy of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: Association of glycated hemoglobin reduction with serum eicosapentaenoic acid and docosahexaenoic acid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy (INTERVAL): a 24 week, randomised, double-blind, placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Experience with vildagliptin in patients ≥75 years with type 2 diabetes and moderate or severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Tolerability and efficacy of glycemic control with saxagliptin in older patients (aged ≥ 65 years) with inadequately controlled type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Safety and efficacy of the dipeptidyl peptidase-4 inhibitor linagliptin in elderly patients with type 2 diabetes: a comprehensive analysis of data from 1331 individuals aged ≥ 65 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Treatment persistence, hypoglycaemia and clinical outcomes in type 2 diabetes patients with dipeptidyl peptidase-4 inhibitors and sulphonylureas: a primary care database analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Avoiding hypoglycemia: a key to success for glucose-lowering therapy in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Efficacy of vildagliptin in combination with insulin in patients with type 2 diabetes and severe renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Long-term efficacy and safety of linagliptin in patients with type 2 diabetes and severe renal impairment: a 1-year, randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Linagliptin treatment in subjects with type 2 diabetes with and without mild-to-moderate renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of alogliptin in chronic kidney disease patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Use of dipeptidyl peptidase-4 inhibitors for the treatment of patients with type 2 diabetes mellitus and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Clinical practice considerations and review of the literature for the Use of DPP-4 inhibitors in patients with type 2 diabetes and chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pharmacokinetics, safety, and efficacy of DPP-4 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes mellitus and renal or hepatic impairment. A systematic review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors: pharmacokinetics, efficacy, tolerability and safety in renal impairment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

DPP-4 inhibitors improve liver dysfunction in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4: a key player in chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The effect of vildagliptin relative to sulphonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: the VIRTUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Incretin action in the pancreas: potential promise, possible perils, and pathological pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Marked expansion of exocrine and endocrine pancreas with incretin therapy in humans with increased exocrine pancreas dysplasia and the potential for glucagon-producing neuroendocrine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Alogliptin after acute coronary syndrome in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Risk of pancreatitis in patients treated with incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The potential risks of pancreatitis and pancreatic cancer with GLP-1-based therapies are far outweighed by the proven and potential (cardiovascular) benefits

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Pancreatic safety of incretin-based drugs--FDA and EMA assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: a critical reappraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular biology of the incretin system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular effects of gliptins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular actions of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

DPP-4 inhibitors and lipids: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

DPP-4 inhibitor and alpha-glucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes: EDGE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Cardiovascular outcome trials in type 2 diabetes and the sulphonylurea controversy: rationale for the active-comparator CAROLINA trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Rationale, design, and baseline characteristics of a clinical trial for prevention of atherosclerosis in patients with insulin-treated type 2 diabetes mellitus using DPP-4 inhibitor: the Sitagliptin Preventive study of Intima-media thickness Evaluat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEAD-A).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: a critical appraisal of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Study to determine the durability of glycaemic control with early treatment with a vildagliptin-metformin combination regimen vs. standard-of-care metformin monotherapy-the VERIFY trial: a randomized double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Diabetic nephropathy: new approaches for improving glycemic control and reducing risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Association between urinary albumin excretion and low-density lipoprotein heterogeneity following treatment of type 2 diabetes patients with the dipeptidyl peptidase-4 inhibitor, vildagliptin: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

DPP-4 inhibition with alogliptin on top of angiotensin II type 1 receptor blockade ameliorates albuminuria via up-regulation of SDF-1α in type 2 diabetic patients with incipient nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

The effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors and heart failure: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidylpeptidase-4 (DPP-4) inhibitors are favourable to glucagon-like peptide-1 (GLP-1) receptor agonists: yes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Comparison of GLP-1 analogues versus sitagliptin in the management of type 2 diabetes: systematic review and meta-analysis of head-to-head studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Choosing between GLP-1 Receptor Agonists and DPP-4 Inhibitors: A Pharmacological Perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Glucagon dynamics during hypoglycaemia and food-re-challenge following treatment with vildagliptin in insulin-treated patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 (DPP-4) inhibitors are favourable to Glucagon-Like Peptide-1 (GLP-1) agonists: No

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2015.978289

10.1517/14656566.2015.978289

21 January 2018

Identifiers

DOI

1 reference

1 September 2017

1 reference